Aegis Biotech, Inc. is a research-driven developer of formularies designed for Medical and Therapeutic applications within Institutional Review Boards settings to the smallest Pediatric patients suffering from DIPG a terminal disease affecting 1 in every 265 children in this country alone. With all types of childhood cancers combined to great disappointment merely receive only 4% of US Federal Funding for cancer research. We would love to see more funding support for the smallest and most innocent of all, children.
Aegis was formed with the passion and purpose of developing and marketing innovative technologies and processes to convert chemical compounds into applications and delivery processes to impact efficacy in indications. Unique to our approach is our ingredient mix designed to eliminate psychoactive effect of Delta 9, making our product development more functional and to a significantly broader patient base.
We advocate and educate awareness within the Clinical settings with Clinicians from all over the world. We are researching a Catheterization to the brain, in conjunction with our Preventative Health and Wellness Protocol using our Patent Process Pending Neutracutical line.
We operate American Cannabis Associations, soon to be released site, where we again advocate and support Global advocacy and education as the research extends into Global territories, we desire to see the positive impact we can make in Pediatric Research. ACA will donate funding for research in various Pediatric studies specific in Cannabidiol studies.
Releasing in late 2017 a Neutracutical product that is for Preventative Wellness, responding in a proactive manner to Neurological health rather than a reactionary one.
We have a strong Clinical Advisory Team, constructed of Top Physicians, Researchers, Educators, and Public Health Members, whose specialties lie within Pediatric Neuroscience, and Cancer Research, all who are eager to see a leadership focused on our smallest target demographic, Pediatrics. This is an exciting time to be in Biotechnology, as we are really able to carve out the future of the therapeutic indications we are able to impact with real efficacy and results.
Member-to Member Benefit: Consulting rates 20% off to Women Grow Members